California Public Employees Retirement System boosted its stake in CryoLife Inc. (NYSE:CRY) by 28.4% during the second quarter, Holdings Channel reports. The fund owned 116,800 shares of the company’s stock after buying an additional 25,800 shares during the period. California Public Employees Retirement System owned approximately 0.34% of CryoLife worth $1,379,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Louisiana State Employees Retirement System increased its position in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the company’s stock valued at $135,000 after buying an additional 100 shares during the last quarter. Spark Investment Management LLC increased its position in shares of CryoLife by 217.6% in the first quarter. Spark Investment Management LLC now owns 39,700 shares of the company’s stock valued at $426,000 after buying an additional 27,200 shares in the last quarter. Swiss National Bank bought a new position in shares of CryoLife during the second quarter valued at approximately $471,000. Emerald Acquisition Ltd. bought a new position in shares of CryoLife during the second quarter valued at approximately $657,000. Finally, Prudential Financial Inc. increased its position in shares of CryoLife by 11.8% in the first quarter. Prudential Financial Inc. now owns 65,404 shares of the company’s stock valued at $703,000 after buying an additional 6,881 shares in the last quarter. Institutional investors own 58.13% of the company’s stock.
CryoLife Inc. (NYSE:CRY) traded down 0.06% during mid-day trading on Thursday, hitting $17.04. The company’s stock had a trading volume of 93,686 shares. CryoLife Inc. has a 52-week low of $8.94 and a 52-week high of $18.64. The stock has a market cap of $581.23 million, a P/E ratio of 54.62 and a beta of 1.05. The company’s 50 day moving average is $17.17 and its 200-day moving average is $13.61.
CryoLife (NYSE:CRY) last posted its quarterly earnings results on Monday, July 25th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.11. CryoLife had a return on equity of 8.15% and a net margin of 5.80%. The firm earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. The company’s revenue was up 32.6% on a year-over-year basis. On average, equities analysts predict that CryoLife Inc. will post $0.34 EPS for the current fiscal year.
CRY has been the subject of several analyst reports. Piper Jaffray Cos. restated an “overweight” rating and issued a $16.00 target price on shares of CryoLife in a research note on Wednesday, July 27th. Lake Street Capital initiated coverage on CryoLife in a research note on Wednesday, June 15th. They issued a “buy” rating and a $15.00 target price for the company. Canaccord Genuity restated a “buy” rating on shares of CryoLife in a research note on Monday, June 20th. Finally, Zacks Investment Research downgraded CryoLife from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. CryoLife has an average rating of “Buy” and a consensus price target of $15.00.
In other news, Director C Elkins Ronald sold 2,000 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the completion of the transaction, the director now owns 103,586 shares in the company, valued at $1,450,204. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.08% of the stock is owned by insiders.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.